Liraglutide in Combination with Insulin Has a Superior Therapeutic Effect to Either Alone on Fracture Healing in Diabetic Rats

References

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi:10.1016/j.diabres.2009.10.007
   PubMed Web of Science ®Google Scholar
• Sun HX, Lu N, Luo X, Zhao L, Liu JM. Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes. 2015;7(4):584–588. doi:10.1111/1753-0407.12282
   PubMed Web of Science ®Google Scholar
• Gortler H, Rusyn J, Godbout C, Chahal J, Schemitsch EH, Nauth A. Diabetes and healing outcomes in lower extremity fractures: a systematic review. Injury. 2018;49(2):177–183. doi:10.1016/j.injury.2017.11.006
   PubMed Web of Science ®Google Scholar
• Claes L, Recknagel S, Ignatius A. Fracture healing under healthy and inflammatory conditions. Nat Rev Rheumatol. 2012;8(3):133–143. doi:10.1038/nrrheum.2012.1
   PubMed Web of Science ®Google Scholar
• Napoli N, Chandran M, Pierroz DD, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208–219. doi:10.1038/nrendo.2016.153
   PubMed Web of Science ®Google Scholar
• Koromani F, Ghatan S, van Hoek M, et al. Type 2 diabetes mellitus and vertebral fracture risk. Curr Osteoporos Rep. 2021;19(1):50–57. doi:10.1007/s11914-020-00646-8
   PubMed Web of Science ®Google Scholar
• Loi F, Cordova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;86:119–130. doi:10.1016/j.bone.2016.02.020
   PubMed Web of Science ®Google Scholar
• Kayal RA, Alblowi J, McKenzie E, et al. Diabetes causes the accelerated loss of cartilage during fracture repair which is reversed by insulin treatment. Bone. 2009;44(2):357–363. doi:10.1016/j.bone.2008.10.042
   PubMed Web of Science ®Google Scholar
• Paglia DN, Wey A, Breitbart EA, et al. Effects of local insulin delivery on subperiosteal angiogenesis and mineralized tissue formation during fracture healing. J Orthop Res. 2013;31(5):783–791. doi:10.1002/jor.22288
   PubMed Web of Science ®Google Scholar
• Gandhi A, Beam HA, O’Connor JP, Parsons JR, Lin SS. The effects of local insulin delivery on diabetic fracture healing. Bone. 2005;37(4):482–490. doi:10.1016/j.bone.2005.04.039
   PubMed Web of Science ®Google Scholar
• Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int. 2009;84(6):453–461. doi:10.1007/s00223-009-9220-3
   PubMed Web of Science ®Google Scholar
• Su B, Sheng H, Zhang M, et al. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107–115. doi:10.1007/s12020-014-0361-4
   PubMed Web of Science ®Google Scholar
• Huang CF, Mao TY, Hwang SJ. The effects of switching from dipeptidyl peptidase-4 Inhibitors to Glucagon-Like Peptide-1 receptor agonists on bone mineral density in diabetic patients. Diabetes Metab Syndr Obes. 2023;16:31–36. doi:10.2147/dmso.S389964
   PubMed Web of Science ®Google Scholar
• Yang L, Yang J, Pan T, Zhong X. Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. J Endocrinol Invest. 2019;42(9):1125–1131. doi:10.1007/s40618-019-01034-5
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res. 2005;52(4):313–320. doi:10.1016/j.phrs.2005.05.004
   PubMed Web of Science ®Google Scholar
• Cao X, Xu P, Oyola MG, et al. Estrogens stimulate serotonin neurons to inhibit binge-like eating in mice. J Clin Invest. 2014;124(10):4351–4362. doi:10.1172/JCI74726
   PubMed Web of Science ®Google Scholar
• Wen B, Zhao L, Zhao H, Wang X. Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis. Exp Ther Med. 2018;15(6):5077–5083. doi:10.3892/etm.2018.6043
   PubMed Web of Science ®Google Scholar
• Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984;2(1):97–101. doi:10.1002/jor.1100020115
   PubMedGoogle Scholar
• Cao GL, Tian FM, Liu GY, et al. Strontium ranelate combined with insulin is as beneficial as insulin alone in treatment of fracture healing in ovariectomized diabetic rats. Med Sci Monit. 2018;24:6525–6536. doi:10.12659/MSM.911573
   PubMed Web of Science ®Google Scholar
• Liu GY, Cao GL, Tian FM, et al. Parathyroid hormone (1-34) promotes fracture healing in ovariectomized rats with type 2 diabetes mellitus. Osteoporos Int. 2017;28(10):3043–3053. doi:10.1007/s00198-017-4148-3
   PubMed Web of Science ®Google Scholar
• Schmidmaier G, Wildemann B, Cromme F, Kandziora F, Haas NP, Raschke M. Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. Bone. 2002;30(6):816–822. doi:10.1016/s8756-3282(02)00740-8
   PubMed Web of Science ®Google Scholar
• Miao D, Scutt A. Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord. 2002;3:16. doi:10.1186/1471-2474-3-16
   PubMed Web of Science ®Google Scholar
• Shifeng L, Hong X, Xue Y, et al. Ac-SDKP increases alpha-TAT 1 and promotes the apoptosis in lung fibroblasts and epithelial cells double-stimulated with TGF-beta1 and silica. Toxicol Appl Pharmacol. 2019;369:17–29. doi:10.1016/j.taap.2019.02.015
   PubMed Web of Science ®Google Scholar
• Komori T. Functions of osteocalcin in bone, pancreas, testis, and muscle. Int J Mol Sci. 2020;21:20. doi:10.3390/ijms21207513
   Web of Science ®Google Scholar
• Depalle B, McGilvery CM, Nobakhti S, Aldegaither N, Shefelbine SJ, Porter AE. Osteopontin regulates type I collagen fibril formation in bone tissue. Acta Bio. 2021;120:194–202. doi:10.1016/j.actbio.2020.04.040
   PubMed Web of Science ®Google Scholar
• Duan P, Bonewald LF. The role of the wnt/beta-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol. 2016;77:23–29. doi:10.1016/j.biocel.2016.05.015
   PubMed Web of Science ®Google Scholar
• Jiao H, Xiao E, Graves DT. Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep. 2015;13(5):327–335. doi:10.1007/s11914-015-0286-8
   PubMed Web of Science ®Google Scholar
• Bai XC, Lu D, Bai J, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun. 2004;314(1):197–207. doi:10.1016/j.bbrc.2003.12.073
   PubMed Web of Science ®Google Scholar
• Figeac F, Tencerova M, Ali D, et al. Impaired bone fracture healing in type 2 diabetes is caused by defective functions of skeletal progenitor cells. Stem Cells. 2022;40(2):149–164. doi:10.1093/stmcls/sxab011
   PubMed Web of Science ®Google Scholar
• Gonzalez Y, Herrera MT, Soldevila G, et al. High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. BMC Immunol. 2012;13:19. doi:10.1186/1471-2172-13-19
   PubMed Web of Science ®Google Scholar
• Picke AK, Gordaliza Alaguero I, Campbell GM, et al. Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone. 2016;82:108–115. doi:10.1016/j.bone.2015.06.001
   PubMed Web of Science ®Google Scholar
• Creecy A, Uppuganti S, Merkel AR, et al. Changes in the fracture resistance of bone with the progression of type 2 diabetes in the ZDSD rat. Calcif Tissue Int. 2016;99(3):289–301. doi:10.1007/s00223-016-0149-z
   PubMed Web of Science ®Google Scholar
• Eom YS, Gwon AR, Kwak KM, et al. Protective effects of vildagliptin against pioglitazone-induced bone loss in type 2 diabetic rats. PLoS One. 2016;11(12):e0168569. doi:10.1371/journal.pone.0168569
   PubMed Web of Science ®Google Scholar
• Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–469. doi:10.1016/j.cell.2007.05.047
   PubMed Web of Science ®Google Scholar
• Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006;99(5):1233–1239. doi:10.1002/jcb.20958
   PubMed Web of Science ®Google Scholar
• Julien A, Perrin S, Duchamp de Lageneste O, et al. FGFR3 in periosteal cells drives cartilage-to-bone transformation in bone repair. Stem Cell Rep. 2020;15(4):955–967. doi:10.1016/j.stemcr.2020.08.005
   PubMed Web of Science ®Google Scholar
• Kayal RA, Siqueira M, Alblowi J, et al. TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res. 2010;25(7):1604–1615. doi:10.1016/j.stemcr.2020.08.005
   PubMed Web of Science ®Google Scholar
• Wong SA, Hu DP, Slocum J, et al. Chondrocyte-to-osteoblast transformation in mandibular fracture repair. J Orthop Res. 2021;39(8):1622–1632. doi:10.1002/jor.24904
   PubMed Web of Science ®Google Scholar
• Shi P, Hou A, Li C, et al. Continuous subcutaneous insulin infusion ameliorates bone structures and mechanical properties in type 2 diabetic rats by regulating bone remodeling. Bone. 2021;153:116101. doi:10.1016/j.bone.2021.116101
   PubMed Web of Science ®Google Scholar
• Hou K, Lin C, Wu B, et al. Exogenetic insulin increased bone mineral density in middle-aged male patients with type 2 diabetes mellitus. Pak J Pharm Sci. 2015;28(6 Suppl):2227–2230.
   PubMed Web of Science ®Google Scholar
• de Waard EAC, Driessen JHM, de Jong JJA, et al. The association between insulin use and volumetric bone mineral density, bone micro-architecture and bone strength of the distal radius in patients with type 2 diabetes - The Maastricht study. Bone. 2017;101:156–161. doi:10.1016/j.bone.2017.05.004
   PubMed Web of Science ®Google Scholar
• Hou CJ, Liu JL, Li X, Bi LJ. Insulin promotes bone formation in augmented maxillary sinus in diabetic rabbits. Int J Oral Maxillofac Surg. 2012;41(3):400–407. doi:10.1016/j.ijom.2011.10.004
   PubMed Web of Science ®Google Scholar
• Gilbert MP, Marre M, Holst JJ, et al. Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr Pract. 2016;22(4):406–411. doi:10.4158/EP15758.OR
   PubMed Web of Science ®Google Scholar
• Lu N, Sun H, Yu J, et al. Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One. 2015;10(7):e0132744. doi:10.1371/journal.pone.0132744
   PubMed Web of Science ®Google Scholar
• Ma X, Meng J, Jia M, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res. 2013;28(7):1641–1652. doi:10.1002/jbmr.1898
   PubMed Web of Science ®Google Scholar
• Sassenrath K, Phillips BB, Stone RH. Evaluation of GLP-1 receptor agonists in combination with multiple daily insulin injections for type 2 diabetes. J Pharm Pract. 2022;35(6):979–990. doi:10.1177/08971900211010678
   PubMed Web of Science ®Google Scholar
• Hou HW, Xue P, Wang Y, Li YK. Liraglutide regulates proliferation, differentiation, and apoptosis of preosteoblasts through a signaling network of Notch/Wnt/Hedgehog signaling pathways. Eur Rev Med Pharmacol Sci. 2020;24(23):12408–12422. doi:10.26355/eurrev_202012_24037
   PubMed Web of Science ®Google Scholar
• Harris K, Nealy KL. The clinical use of a fixed-dose combination of insulin degludec and liraglutide (Xultophy 100/3.6) for the treatment of type 2 diabetes. Ann Pharmacother. 2018;52(1):69–77. doi:10.1177/1060028017726348
   PubMed Web of Science ®Google Scholar
• Wysham CH, Campos C, Kruger D. Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), two novel co-formulations of a basal insulin and a glucagon-like peptide-1 receptor agonist, in patients with diabetes not adequately controlled on oral antidiabetic medications. Clin Diabetes. 2018;36(2):149–159. doi:10.2337/cd17-0064
   PubMedGoogle Scholar